...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer.
【24h】

Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer.

机译：估计预后的价值Bcl-xL基因在非小细胞肺癌表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of our study was to estimate the expression of the Bcl-xL gene, a member of Bcl-2 family, in NSCLC patients. A total of 60 consecutive patients diagnosed with NSCLC that underwent chemotherapy prior to surgery were reviewed. Bcl-xL expression was assessed on paraffin sections by in situ hybridization (ISH) and immunohistochemistry (IMH). We observed the presence of mRNA of Bcl-xL gene and its protein product overexpression in most patients (60 and 81.7%, respectively). In material examined no significant correlation was observed between the pattern of Bcl-xL or protein expression and any clinicopathological factors evaluated. The expression of Bcl-xL protein was low (less than 10% positive cells) in 11 patients (median survival time 29 months) as compared to 49 patients with overexpression (median survival time 21.0 months). The difference was not of statistic significance (p=0.27). In examined group the Bcl-xL mRNA was found in 36 patients, while it was absent in 24 cases. Median survival timewas 14.5 and 86.5 months, respectively (p=0.001). In addition, 19.4% of 5-year survivals were achieved in patients with overexpression and 54.2% in patients with no mRNA present (p=0.002). The percentage of 5-year survival in patients with protein expression assessed by IMH was 30.6% (p=0.31). The estimation of Bcl-xL expression on mRNA and protein level was compared by the means of sign test and the significant difference was found (p=0.009). The inconsistency was related to 35% of cases. In comparison with IMH, ISH technique appeared to be more specific and accurate in assessment of 5-year survival (25 and 65%; 65 and 70%, respectively). The results of our study indicate that Bcl-xL mRNA overexpression may suggest poor prognosis in NSCLC.
机译：我们的研究的目的是评估成员表达Bcl-xL基因bcl - 2家庭,在非小细胞肺癌患者。诊断为非小细胞肺癌病人连续接受化疗前手术回顾。石蜡切片的原位杂交(ISH)和免疫组织化学(IMH)。Bcl-xL基因的mRNA和蛋白的存在产品在大多数病人(60和超表达分别为81.7%)。之间的显著相关性观察的Bcl-xL或蛋白质表达和任何模式临床病理的因素进行评估。Bcl-xL蛋白质的表达很低(不到在11个患者(平均10%的阳性细胞)生存时间29个月)比49过度患者(中位数生存时间21.0个月)。统计意义(p = 0.27)。小组发现Bcl-xL mRNA的36例,虽然没有在24例。分别timewas 14.5和86.5个月(p = 0.001)。实现超表达与患者吗54.2%的患者没有信使rna (p = 0.002)。患者的5年生存的百分比与蛋白表达评估IMH是30.6%(p = 0.31)。信使rna和蛋白质水平比较的意思符号检验和显著差异发现(p = 0.009)。35%的病例。技术似乎更具体的和5年存活率(25和准确的评估65%;我们的研究表明Bcl-xL信使rna超表达可能提示预后不良非小细胞肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号